Shalini Singh | Clinical Pharmacology | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Shalini Singh
Global Cosmetic Regulatory Services Pvt Ltd, India

Shalini Singh
Affiliation Global Cosmetic Regulatory Services Pvt Ltd
Country India
Google Scholar N3KRvykAAAAJ
Documents 41
Citations 159
h-index 7
Subject Area Clinical Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3743-8888

Shalini Singh is an Indian researcher associated with Global Cosmetic Regulatory Services Pvt Ltd, where her work focuses on clinical pharmacology, pharmaceutical regulation, cosmetic science, regulatory compliance, and healthcare quality. Her scholarly contributions demonstrate sustained engagement in pharmaceutical research, evidence-based regulatory practices, and scientific documentation. Through peer-reviewed publications and collaborative investigations, she has contributed to improving regulatory understanding and pharmaceutical safety within both academic and industrial environments.[1] Her research profile reflects interdisciplinary expertise spanning clinical pharmacology, pharmaceutical sciences, cosmetic regulation, and healthcare innovation.[2]

Abstract

Shalini Singh has established a research portfolio centered on clinical pharmacology, cosmetic regulatory affairs, pharmaceutical quality systems, and healthcare compliance. Her scholarly work emphasizes the integration of scientific evidence with regulatory frameworks to support safe pharmaceutical development, effective cosmetic product evaluation, and quality assurance practices. Through published research and professional collaborations, she has contributed to advancing regulatory science while promoting responsible innovation across pharmaceutical and cosmetic industries. Her publication record, citation profile, and continued academic engagement indicate consistent participation in multidisciplinary pharmaceutical research.[1][3]

Keywords

Clinical Pharmacology, Regulatory Affairs, Cosmetic Regulations, Pharmaceutical Sciences, Drug Safety, Pharmacovigilance, Regulatory Compliance, Healthcare Quality, Pharmaceutical Quality Assurance, Cosmetic Science, Evidence-Based Medicine, Pharmaceutical Documentation, Clinical Research, Drug Development, Regulatory Science, Product Safety, Pharmaceutical Innovation, Healthcare Regulations, Scientific Publishing, Pharmaceutical Policy.

Introduction

Clinical pharmacology and pharmaceutical regulation play essential roles in ensuring the safety, efficacy, and quality of healthcare products throughout their life cycle. Researchers working in these fields contribute to scientific advancement by strengthening regulatory systems, supporting evidence-based decision-making, and improving public health outcomes. Regulatory professionals also facilitate the translation of scientific discoveries into compliant pharmaceutical and cosmetic products that meet international standards.[2]

Research Profile

The academic profile of Shalini Singh reflects sustained contributions to pharmaceutical sciences with emphasis on clinical pharmacology and regulatory science. Her scholarly metrics include forty-one indexed publications, one hundred fifty-nine citations, and an h-index of seven, indicating continued academic visibility and citation impact within her research community.[1]

Research Contributions

Shalini Singh has contributed to pharmaceutical and clinical research through publications focusing on regulatory science, cosmetic product compliance, pharmaceutical quality assurance, drug safety, and evidence-based healthcare practices. Her research supports the development of scientifically validated regulatory frameworks while encouraging harmonization between pharmaceutical innovation and international compliance standards.[2][3]

Publications

The publication portfolio of Shalini Singh demonstrates continuous scholarly activity within pharmaceutical sciences and clinical pharmacology. Her research output includes peer-reviewed articles addressing regulatory science, pharmaceutical development, healthcare quality, cosmetic regulations, and related multidisciplinary areas. Collectively, these publications have contributed to academic discussions concerning pharmaceutical quality assurance and regulatory compliance.[1]

Research Impact

The measurable research impact of Shalini Singh is reflected through publication productivity, citation performance, and continuing engagement with pharmaceutical and regulatory research communities. Her work contributes to scientific understanding of clinical pharmacology, pharmaceutical quality systems, cosmetic regulation, and healthcare policy. Citation indicators demonstrate that her publications have been referenced by subsequent investigations, supporting ongoing knowledge development within pharmaceutical sciences.[1][2]

Award Suitability

Based on her documented publication record, research activity, citation profile, and professional engagement within clinical pharmacology and pharmaceutical regulation, Shalini Singh demonstrates characteristics commonly associated with recognition under the Women Researcher Award presented at the International Top Pharmaceutical Awards. Her contributions illustrate sustained scholarly participation, interdisciplinary collaboration, and commitment to advancing pharmaceutical sciences through research and regulatory excellence.[1][3]

Conclusion

Shalini Singh has established a professional research profile that combines clinical pharmacology, pharmaceutical regulation, cosmetic compliance, and healthcare quality assurance. Through consistent scholarly publications, interdisciplinary collaboration, and evidence-based regulatory research, she contributes to the advancement of pharmaceutical sciences and responsible healthcare innovation. Her academic achievements, publication metrics, and continuing scientific engagement provide a strong foundation for professional recognition within international pharmaceutical research communities.[1][4]

References

  1. Google Scholar. (n.d.). Shalini Singh – Google Scholar Profile. https://scholar.google.com/citations?user=N3KRvykAAAAJ
  2. Singh, S., Arya, V., Mishra, R. K., & Rajput, S. K. (2026). Clinical Effectiveness of Naturopathic Therapeutic Approaches in the Management of Polycystic Ovary Syndrome: Real-World Evidence. Current Indian Science. Advance online publication. https://doi.org/10.2174/012210299X481816260630115057
  3. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., Mishra, S., & Rana, M. (2025). Mechanistic and Phytopharmacological Insights into Ayurvedic Botanicals for the Management of Polycystic Ovarian Syndrome. Journal of Ayurvedic and Herbal Medicine. https://doi.org/10.4103/JAHM.JAHM_55_25
  4. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research. https://doi.org/10.1016/j.nexres.2024.100004
  5. Balkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., Arya, V., & Rigano, D. (2023). Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine. 
    https://doi.org/10.1155/2023/3705508

May Abdullah Almoshary | Hematology | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

May Abdullah Almoshary
Princess Nourah Bint Abdulrahman University, Saudi Arabia
May Abdullah Almoshary
Affiliation Princess Nourah Bint Abdulrahman University
Country Saudi Arabia
Scopus ID 57193323753
Documents 11
Citations 103
h-index 5
Subject Area Hematology
Event International Top Pharmaceutical Awards
ORCID 0000-0003-4839-5032

The Innovative Research Award recognizes distinguished scholarly achievement, sustained scientific productivity, and meaningful contributions to academic advancement within specialized research disciplines. This article presents a structured overview of the academic profile of May Abdullah Almoshary, whose published work in hematology demonstrates continuous engagement in clinical investigation, evidence-based practice, and interdisciplinary collaboration. The available bibliometric indicators and internationally indexed publications provide an objective basis for evaluating research visibility and scholarly influence within the biomedical sciences.[1]

Abstract

May Abdullah Almoshary has established an academic profile characterized by sustained research activity in hematology and related biomedical disciplines. Her scholarly work reflects a commitment to improving scientific understanding through clinical investigation, collaborative research, and publication in internationally indexed journals. Citation performance, publication metrics, and institutional affiliation collectively indicate continued engagement with contemporary medical research and knowledge dissemination. The Innovative Research Award acknowledges researchers whose scientific contributions demonstrate originality, measurable impact, and ongoing professional development. .[2]

Keywords

Innovative Research Award, Hematology, Clinical Research, Biomedical Science, Princess Nourah Bint Abdulrahman University, Scopus, Scientific Publications, Medical Research, Research Excellence, International Top Pharmaceutical Awards.

Introduction

Recognition through international academic awards emphasizes research quality, scientific integrity, and measurable scholarly contribution. Modern evaluation frameworks frequently incorporate publication productivity, citation performance, collaborative engagement, and research relevance when assessing candidates for research recognition. Bibliometric databases further provide transparent indicators that assist institutions and professional organizations in identifying researchers whose work demonstrates sustained academic influence.[1]

Research Profile

May Abdullah Almoshary is affiliated with Princess Nourah Bint Abdulrahman University in Saudi Arabia and has developed an active research portfolio within hematology. According to publicly available Scopus indexing records, the researcher has authored eleven indexed publications, accumulated more than one hundred citations, and achieved an h-index of five. These indicators reflect continued participation in internationally visible scientific research while demonstrating consistent academic productivity and citation impact across published work. Her publications illustrate participation in collaborative biomedical investigations addressing clinically significant topics relevant to hematological disorders, laboratory diagnostics, and patient-centered healthcare. [2]

Research Contributions

The research contributions of May Abdullah Almoshary are centered on advancing knowledge in hematology through clinical investigations, collaborative biomedical research, and evidence-based scientific reporting. Her studies address topics that support improved understanding of blood disorders, laboratory medicine, patient management, and translational healthcare. The integration of clinical observations with modern research methodologies has strengthened the practical relevance of her published work while contributing to the growing body of international hematology literature.[2]

Publications

The publication record reflects sustained scholarly engagement in hematology and related biomedical sciences through peer-reviewed academic journals. The published studies address clinically relevant topics, contribute to scientific understanding, and support evidence-based healthcare practices across diverse medical settings. The research demonstrates consistent collaboration with national and international scholars while emphasizing methodological quality, scientific integrity, and practical clinical relevance. Collectively, these publications strengthen academic visibility, encourage interdisciplinary knowledge exchange, and provide valuable scientific evidence that supports future investigations and continued advancement within the field of hematology.[1][2]

Research Impact

Bibliometric indicators provide measurable evidence of scholarly influence and research visibility. According to publicly available Scopus records, May Abdullah Almoshary has produced eleven indexed publications, received more than one hundred citations, and achieved an h-index of five. These metrics demonstrate that her work has been recognized and referenced within the international scientific community while reflecting sustained academic engagement in hematology research.Continued citation activity indicates the ongoing relevance of her research within biomedical science and supports the dissemination of reliable clinical knowledge across international academic networks.[2]

Award Suitability

The Innovative Research Award recognizes originality, scientific quality, measurable research impact, and sustained scholarly excellence. Based on the available publication record, bibliometric indicators, international indexing, and continued contribution to hematology research, May Abdullah Almoshary demonstrates characteristics consistent with the objectives of the International Top Pharmaceutical Awards. Her research profile reflects scientific integrity, collaborative engagement, and continued commitment to advancing biomedical knowledge through peer-reviewed investigation.[1][2]

Conclusion

The academic achievements of May Abdullah Almoshary illustrate a sustained commitment to scientific excellence within hematology and biomedical research. Through internationally indexed publications, measurable citation impact, and collaborative scientific activity, the researcher has contributed to the advancement of evidence-based medical knowledge. These accomplishments align with internationally recognized standards for academic distinction and support consideration for professional research recognition through the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus Author Details: May Abdullah Almoshary (Author ID: 57193323753). Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57193323753
  2. AlMoshary, M. (2026). Living with sickle cell disease in the Arab world: Quality of life beyond clinical severity. Blood Cells, Molecules, and Diseases.
    https://doi.org/10.1016/j.bcmd.2026.103026
  3. AlMoshary, M., et al. (2024). The role of prophylactic transfusion on the maternal and fetal outcomes in pregnant women with sickle cell disease: A systematic review and meta-analysis. Medicine.
    https://doi.org/10.1097/MD.0000000000039475
  4. Bakhsh, E., Shaban, M., Al Subaie, S., Al Moshary, M., & AlSheef, M. (2023). Exploring the Clinical Efficacy of Venous Thromboembolism Management in Saudi Arabian Hospitals: An Insight into Patient Outcomes. Journal of Personalized Medicine, 13(4).
    https://www.mdpi.com/2075-4426/13/4/612
  5. Bakr, S., AlFattani, A., Al-Nounou, R., et al. (2022). Hematologic reference intervals for healthy adult Saudis. Annals of Saudi Medicine, 42.
    https://doi.org/10.5144/0256-4947.2022.191

Nicusor Iftimia | Precision Medicine | Innovative Research Award | 2701

Published on by Top Pharmaceutical

Innovative Research Award

Nicusor Iftimia
PSI, United States

Research Profile
Affiliation PSI
Country United States
Scopus ID 6603766089
Documents 177
Citations 4,524
h-index 36
Subject Area Precision Medicine
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7713-6972

The Innovative Research Award recognizes researchers whose sustained scientific contributions have significantly advanced their respective disciplines through original research, technological innovation, and scholarly impact. Nicusor Iftimia has established a distinguished research profile in precision medicine and biomedical imaging, with extensive publications, a strong citation record, and interdisciplinary contributions that have influenced translational healthcare research.[1] His scholarly work spans optical imaging technologies, diagnostic instrumentation, and clinical applications that support improved patient outcomes.[2]

Abstract

Nicusor Iftimia has developed an internationally recognized research portfolio focused on precision medicine, biomedical optics, and advanced diagnostic technologies. His scientific investigations have supported improvements in optical coherence tomography, image-guided diagnostics, and translational biomedical engineering. The combination of a high publication output, extensive citations, and measurable scholarly influence demonstrates the sustained academic excellence expected for recognition through the Innovative Research Award.[1]

Keywords

Precision Medicine, Optical Coherence Tomography, Biomedical Imaging, Diagnostic Instrumentation, Biomedical Engineering, Clinical Imaging, Medical Devices, Translational Medicine, Optical Diagnostics, Innovative Research.

Introduction

Precision medicine continues to transform healthcare by integrating advanced imaging technologies with patient-specific diagnostic strategies. Researchers working at the intersection of engineering, optics, and medicine contribute substantially to this evolving field through innovations that improve disease detection and clinical decision-making. Nicusor Iftimia has consistently contributed to these developments through multidisciplinary research involving optical technologies and biomedical instrumentation.[2]

Research Profile

Nicusor Iftimia has established a distinguished research profile in precision medicine through extensive contributions to biomedical optics, optical coherence tomography, and advanced medical imaging technologies. His academic portfolio comprises 177 Scopus-indexed publications, more than 4,524 citations, and an h-index of 36, demonstrating sustained scholarly productivity and international research influence. His work emphasizes the development of innovative diagnostic methods and translational biomedical engineering solutions that bridge laboratory research with clinical practice. The breadth of his publications, collaborative research activities, and measurable scientific impact highlight his continued contributions to advancing precision medicine and healthcare technologies.[1][2]

Research Contributions

The research contributions of Nicusor Iftimia emphasize the integration of optical technologies with clinical practice. His publications have supported advances in non-invasive imaging, medical diagnostics, and translational biomedical engineering, enabling more accurate disease assessment and supporting innovation within precision healthcare systems.[3]

Publications

Nicusor Iftimia has authored 177 Scopus-indexed publications covering precision medicine, biomedical optics, optical coherence tomography, medical imaging, and diagnostic instrumentation. His scholarly work has been published in internationally recognized peer-reviewed journals and conference proceedings, demonstrating consistent research productivity and interdisciplinary collaboration. These publications have significantly contributed to the advancement of non-invasive imaging technologies, clinical diagnostics, and translational biomedical engineering. The sustained quality and impact of his research output are reflected by a strong citation record and continued recognition within the global scientific community.[1][2]

Research Impact

The citation metrics and publication record indicate sustained international recognition within biomedical engineering and medical imaging. The research has contributed to technological innovation, interdisciplinary collaboration, and scientific knowledge transfer across academic and healthcare communities.[1]

Award Suitability

Based on measurable scholarly indicators, interdisciplinary research contributions, and international scientific visibility, Nicusor Iftimia demonstrates characteristics consistent with the objectives of the International Top Pharmaceutical Awards. His sustained research productivity, technological innovation, and influence within precision medicine provide a strong academic foundation for consideration for the Innovative Research Award.[4]

Conclusion

Nicusor Iftimia’s academic profile reflects long-term excellence in biomedical optics, precision medicine, and diagnostic innovation. His publication history, citation impact, and interdisciplinary research achievements illustrate continued contributions to scientific advancement and demonstrate the qualities recognized through international research excellence awards.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nicusor Iftimia, Author ID 6603766089. Scopus. https://www.scopus.com/authid/detail.uri?authorId=6603766089
  2. Iftimia, N., Yadav, P., Primrose, M., Maguluri, G., Jones, J., Grimble, J., & Sheth, R. A. (2026). AI-Assisted OCT Imaging for Core Needle Biopsy Guidance: The 1st in Humans Study. https://doi.org/10.3390/diagnostics16050811
  3. Sampani, K., Mujat, M., Patel, A. H., Kang, C., Iftimia, N., Chatziralli, I., & Sun, J. K. (2024). Characterizing Vascular Wall and Lumen Caliber in Eyes with Diabetic Retinopathy Based on Adaptive Optics Scanning Laser Ophthalmoscopy. https://doi.org/10.3390/diagnostics14182020
  4. Steinberg, R., Meehan, J., Tavrow, D., Maguluri, G., Grimble, J., Primrose, M., & Iftimia, N. (2024). Assessing Lung Fibrosis with ML-Assisted Minimally Invasive OCT Imaging.https://doi.org/10.3390/diagnostics14121243
  5. Maguluri, G., Grimble, J., Mujat, M., Park, J., Caron, A., & Iftimia, N. (2022). Fiber-based hand-held RCM-OCT probe for noninvasive assessment of skin lesions and therapy guidance. https://doi.org/10.1002/tbio.202200002

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Walter Manucha | Nanopharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Walter Manucha
National Scientific and Technical Research Council, Argentina
Walter Manucha
Affiliation National Scientific and Technical Research Council
Country Argentina
Scopus ID 57195218813
Documents 2665
Citations 3316
h-index 34
Subject Area Nanopharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-2279-7626

Walter Manucha is a researcher affiliated with the National Scientific and Technical Research Council in Argentina, with academic contributions associated with nanopharmacology, biomedical sciences, and translational therapeutic research. His scholarly profile reflects extensive publication activity, interdisciplinary scientific collaboration, and measurable citation performance within international indexing systems.[1] The recognition associated with the Best Researcher Award acknowledges sustained research productivity, scientific influence, and contributions to pharmaceutical and biomedical advancement within an international academic framework.[2]

Abstract

The Best Researcher Award article documents the academic profile and research standing of Walter Manucha in the field of nanopharmacology and pharmaceutical sciences. The article summarizes publication metrics, scholarly influence, interdisciplinary contributions, and international research visibility indexed through global academic databases.[1] It also evaluates the researcher’s suitability for recognition under the International Top Pharmaceutical Awards framework, emphasizing scientific productivity, citation impact, and contributions to biomedical innovation.[2]

Keywords

Nanopharmacology, Pharmaceutical Sciences, Biomedical Research, Drug Delivery, Translational Medicine, Scopus Metrics, Scientific Impact, Research Excellence, International Awards, Academic Recognition

Introduction

Academic recognition programs in pharmaceutical sciences frequently evaluate candidates using publication performance, citation analysis, interdisciplinary collaboration, and international scientific influence. Walter Manucha’s research activities are associated with nanopharmacology and therapeutic innovation, areas that continue to contribute to modern biomedical and pharmaceutical development.[1] Through indexed scholarly publications and measurable citation metrics, the researcher demonstrates sustained participation in peer-reviewed scientific advancement and international academic communication.[3]

Research Profile

Walter Manucha is affiliated with the National Scientific and Technical Research Council in Argentina and has developed a research profile connected to nanopharmacology, pharmaceutical sciences, and biomedical investigation. The Scopus-indexed profile records substantial publication activity and measurable scholarly visibility through citations and h-index indicators.[1] His academic contributions demonstrate participation in multidisciplinary scientific collaboration and translational research themes relevant to therapeutic sciences and clinical innovation.[4]

  • Institutional affiliation with the National Scientific and Technical Research Council.
  • Research specialization associated with nanopharmacology and biomedical sciences.
  • Scopus-indexed publication and citation visibility.
  • International academic dissemination and interdisciplinary collaboration.

Research Contributions

The researcher’s scientific activities contribute to areas related to drug development, therapeutic mechanisms, biomedical applications, and pharmaceutical innovation. Nanopharmacology represents an emerging interdisciplinary field integrating nanotechnology with pharmacological sciences to improve targeted therapeutic approaches and biomedical efficiency.[4] The research output associated with Walter Manucha reflects scholarly engagement with evolving pharmaceutical technologies and evidence-based biomedical methodologies.[5]

  • Development of interdisciplinary biomedical research frameworks.
  • Contributions to therapeutic and pharmaceutical sciences.
  • Scientific dissemination through indexed journal publications.
  • Participation in internationally recognized research communication platforms.

Publications

The publication record associated with Walter Manucha reflects extensive participation in scholarly communication and indexed scientific literature. Indexed databases identify numerous publications linked to pharmaceutical sciences and biomedical research themes.[1] Publication visibility and citation engagement indicate active dissemination within the international scientific community.[3]

  1. Research articles in nanopharmacology and biomedical sciences.
  2. Peer-reviewed publications indexed in international databases.
  3. Collaborative scientific contributions in pharmaceutical research.
  4. Publications contributing to translational and therapeutic innovation.

Research Impact

Research impact indicators demonstrate measurable academic visibility through citation performance, indexed publications, and h-index evaluation. Citation activity associated with the researcher indicates that published works have contributed to ongoing scientific discussion and scholarly reference within related biomedical domains.[1] The h-index score further reflects sustained research productivity and academic engagement over time.[3]

  • Scopus-indexed visibility and citation accumulation.
  • Sustained publication activity within pharmaceutical sciences.
  • Research dissemination through international scholarly networks.
  • Academic influence reflected through measurable bibliometric indicators.

Award Suitability

The Best Researcher Award recognizes sustained scientific contribution, publication excellence, and measurable academic impact within pharmaceutical and biomedical sciences. Walter Manucha’s documented research metrics, publication record, and interdisciplinary scientific involvement demonstrate alignment with the evaluative principles commonly associated with international academic recognition programs.[2] The researcher’s profile indicates scholarly consistency, international indexing visibility, and participation in evidence-based scientific advancement relevant to nanopharmacology and translational biomedical research.[5]

Conclusion

Walter Manucha’s academic profile reflects sustained scientific productivity, interdisciplinary collaboration, and measurable scholarly visibility within pharmaceutical and biomedical sciences. Through indexed publications, citation performance, and contributions associated with nanopharmacology, the researcher demonstrates continued engagement with internationally recognized scientific research activities.[1] The documented academic metrics and research dissemination support recognition under the Best Researcher Award category within the International Top Pharmaceutical Awards framework.[2]

References

  1. Elsevier. (n.d.). Scopus author details: Walter Manucha, Author ID 57195218813. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57195218813
  2. International Top Pharmaceutical Awards. (n.d.). Academic recognition and pharmaceutical research excellence platform.
    https://toppharmaceutical.org/
  3. Martín Gimenez, V. M., García Menendez, S., & Manucha, W. (2026). Multi-endogenous nanoformulation for endocannabinoid and hormonal modulation of key signaling pathways in resistant hypertension. Current Pharmaceutical Design.
    https://doi.org/10.2174/0113816128396666250728074858
  4. Reiter, R. J., Sharma, R., Loh, D., Chuffa, L. G. A., Bai, Y., Zuccari, D. A. P. C., Galano, A., & Manucha, W. (2026). Melatonin targets mitochondrial redox homeostasis: Optimizing the intracellular microenvironment. International Journal of Molecular Sciences.
    https://doi.org/10.3390/ijms27104496
  5. Carloni, S., Luchetti, F., Nasoni, M. G., Balduini, W., Manucha, W., & Reiter, R. J. (2026). Melatonin and mitochondrial stress: New insights into age-related neurodegeneration. Neural Regeneration Research.
    https://doi.org/10.4103/NRR.NRR-D-24-01380

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Dr. Surya Nandan Meena, Savitribai Phule Pune University, India

Dr. Surya Nandan Meena is an accomplished researcher in natural product chemistry with over 7 years of postdoctoral experience. He has authored 16 peer-reviewed publications, 4 books, and 8 book chapters, focusing on anticancer and antidiabetic compound discovery. 🧬 His expertise spans LC-MS/MS, molecular docking, and mammalian cell assays. 🎓 A recipient of prestigious fellowships like the Dr. D.S. Kothari and SERB-DST, he has led international projects, mentored students, and contributed to multidisciplinary science globally. 🌱 Passionate about drug discovery and marine biotechnology, Dr. Meena actively serves on editorial boards and scientific societies worldwide.

Publication Profile

Google Scholar

Education

Dr. Surya Nandan Meena is a dedicated scholar with a robust academic background in biotechnology and agriculture. He earned his Ph.D. in Biotechnology from Goa University, India (Nov 2010 – April 2017), where he conducted extensive research in the field. Prior to that, he completed his M.Sc. in Plant Biotechnology from UAS Dharwad, India (July 2006 – April 2009), further refining his expertise in plant sciences 🌿. His academic journey began with a B.Sc. (Hons) in Agriculture from MPUAT, Udaipur, Rajasthan (July 2002 – June 2006) 🌾, laying a strong foundation for his future contributions to agricultural biotechnology.

Awards

Dr. Surya Nandan Meena has been honored with numerous prestigious awards and research fellowships throughout his academic journey. In 2019, he received the Kothari Postdoctoral Research Fellowship from UGC, India. He earned the Best Research Paper Appreciation Award from Anchrome Pvt. Ltd. in 2018 📜. In 2017, he was awarded the National Postdoctoral Fellowship by SERB-DST, India. His dedication was also recognized with the Senior Research Fellowship from DBT in 2013 and the Best Poster Presentation Award in 2012 🧪. Earlier, he secured the Junior Research Fellowship from DBT in 2009 and the JNU CEEB Fellowship in 2006 🎓.

Experience

Dr. Surya Nandan Meena brings a wealth of professional experience in biotechnology and marine research. Since Nov 2019, he has served as a Postdoctoral Fellow at Pune University, conducting mammalian cell-based assays and characterizing bioactive seaweed compounds 🌊. Earlier, at the National Institute of Oceanography (2017–2019), he surveyed 35+ seaweed species and contributed to multiple publications 📚. As a Senior Research Fellow at ICAR-CCARI (2016–2017), he identified beneficial microbial strains 🌱 and developed plant growth formulations. His roles also included mentoring students, publishing in high-impact journals, and leading interdisciplinary research, reflecting his dedication to scientific innovation and collaboration 👨‍🔬.

Research Focus

Dr. Surya Nandan Meena’s research centers on natural product chemistry, sustainable bioresource utilization, and drug discovery. His work bridges the gap between marine and terrestrial natural compounds for therapeutic applications, especially targeting antidiabetic, antioxidant, and anticancer properties. With notable contributions in biocatalysis, phytochemistry, and biosynthetic pathways, Dr. Meena emphasizes green, solvent-free synthesis and eco-friendly resource management. He actively explores seaweed farming, plant-based compounds, and essential oils as potent sources for novel bioactives. His multidisciplinary approach contributes significantly to natural compound-based drug development and sustainable healthcare innovation.

Publication Top Notes

Natural resources conservation and advances for sustainability

Graphite catalyzed solvent free synthesis of dihydropyrimidin-2 (1H)-ones/thiones and their antidiabetic activity

Seaweed Farming: A Perspective of Sustainable Agriculture and Socio-economic Development

Advances in Biological Science Research: A Practical Approach

Biosynthesis of vanillic acid by Ochrobactrum anthropi and its applications

α-Glucosidase inhibition activity and in silico study of 2-(benzo [d][1, 3] dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone

Quick Identification of Piperidine Alkaloid from Roots of Grewia nervosa and Their Glucosidase Inhibitory Activity

Antioxidant and antiglycemic properties of macroalgae, an underutilized blue economy bioresource in India

Evaluation of silver-doped indium oxide nanoparticles as in vitro α-amylase and α-glucosidase inhibitors

New horizons in natural compound research

Biodegradation of seafood waste by seaweed-associated bacteria and application of seafood waste for ethanol production

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, “Mariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace 🎓 is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases 🔥🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome “Tor Vergata” 🏥, graduating cum laude with a thesis on hybrid imaging 🧠📸. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging 🫀🧬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at “Mariano Santo” Hospital in Cosenza, Italy ⚛️🏥. From May 2016 to September 2017, he worked at the Department of Radiology, “Annunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome 🏛️🔬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) 🔬🧠. His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health 🧬💡. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Jameel Al-Tamimi | Biopharmaceutics | Best Researcher Award

Published on by Top Pharmaceutical

Jameel Al-Tamimi | Biopharmaceutics | Best Researcher Award

Dr. Jameel Al-Tamimi, King Saud University, Saudi Arabia

Dr. Jameel Al-Tamimi is a distinguished researcher with a Ph.D. in Immunogenetics from King Saud University, Riyadh, Saudi Arabia. His research focuses on immunology, particularly the role of Killer Immunoglobulin-like Receptors (KIRs) in leukemia. He has expertise in molecular techniques, immunology, and forensic entomology. Dr. Al-Tamimi has published numerous research articles and has contributed to various academic committees. His teaching experience spans courses in molecular biology, human physiology, and medical entomology.

Publication Profile

Google Scholar

Education

Dr. Jameel Al-Tamimi 🎓 is a distinguished researcher with a Ph.D. in Immunogenetics (Excellent 4.9/5) from King Saud University, where his thesis explored the Role of Killer Immunoglobulin-like Receptors (KIRs) with HLA Ligands in Saudi Leukemia Patients 🧬. He also holds an M.Sc. in Entomology and Parasitology (Excellent 4.9/5), investigating the anti-inflammatory effects of Pachycondyla sennaarensis (Samsum Ant) venom in male albino rats 🐜🧪. Dr. Al-Tamimi earned his B.Sc. in Biology (Very Good 89.9/100) from Thamar University, Yemen, with research focused on physiological changes in viral hepatitis (HbsAg and HCV) patients at Thamar Hospital 🧫🦠.

Experience

Dr. Jameel Al-Tamimi 🧑‍🔬 brings a wealth of academic and research experience. Since 2023, he has served on the Scientific Committee for the Researcher Support Program (RSPD) and Research Groups Program (RGP) at the Deanship of Scientific Research 📚. At King Saud University, he contributed to key committees, including labs, academic accreditation, exams, and graduate studies 🏛️. He supervised both the endocrinology and immunology laboratories 🧪 and mentored undergraduate and master’s students 🎓. Skilled in handling rats, mice, and insects 🐭🦗, Dr. Al-Tamimi is also proficient in advanced molecular biology, immunology, and physiology techniques 🧬🔬.

Awards

Dr. Jameel Al-Tamimi 🎓 has been recognized for his academic excellence with several prestigious awards. In 2015, he received an acknowledgment certificate from the Chairman of the Center of Excellence in the Development of Science and Mathematics Education at King Saud University 🏅, highlighting his contribution to scientific advancement. Earlier, in 2013, he was honored with a Certificate of Appreciation (General Prize) during the first Graduate Student Annual Scientific Meeting at KSU 📜🎉. These achievements reflect his dedication to academic excellence, innovation in research, and commitment to the scientific community 🌟📚.

Research Focus

Dr. Jameel Al-Tamimi is a multidisciplinary biomedical researcher whose primary focus lies in oxidative stress, wound healing, diabetes, and nanoparticle therapeutics. His work spans nanomedicine, immunomodulation, and natural product pharmacology, particularly in evaluating the biological activities of camel milk peptides, selenium and zinc oxide nanoparticles, and bioactive plant extracts. Dr. Al-Tamimi’s studies contribute significantly to redox biology, diabetic complications, and biofabrication of therapeutic agents, offering innovative strategies for combating chronic diseases and enhancing healing processes. 🧫💊🐫 His collaborative work reflects a strong emphasis on toxicology, regenerative medicine, and bio-nanotechnology.

Publication Top Notes

Camel milk peptide improves wound healing in diabetic rats by orchestrating the redox status and immune response

Wound healing of different molecular weight of hyaluronan; in-vivo study‏

Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress‏

Synthesis, structural characterization of silver (I)-NHC complexes and their antimicrobial, antioxidant and antitumor activities‏

Potential effects of the combination of nicotinamide, vitamin B2 and vitamin C on oxidative-mediated hepatotoxicity induced by thioacetamide‏

Efficacy of a Methanolic Extract of Adansonia digitata Leaf in Alleviating Hyperglycemia, Hyperlipidemia, and Oxidative Stress of Diabetic Rats‏

Antioxidant Bioactivity of Samsum Ant (Pachycondyla sennaarensis) Venom Protects against CCL4‐Induced Nephrotoxicity in Mice‏

Biofabrication of Zinc Oxide Nanoparticle from Ochradenus baccatus Leaves: Broad‐Spectrum Antibiofilm Activity, Protein Binding Studies, and In Vivo Toxicity …‏

Xia Xiao | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Xia Xiao | Pharmacodynamics | Best Researcher Award

Assoc. Prof. Dr. Xia Xiao, Yangzhou University, China

Assoc. Prof. Dr. Xia Xiao is a distinguished researcher in veterinary microbiology at Yangzhou University. He earned his Ph.D. in Veterinary Science from South China Agricultural University (2015) 🎓, specializing in bacteriophage-mediated antibiotic resistance. His research focuses on antimicrobial pharmacokinetics, novel antimicrobial agents, and bacterial resistance mechanisms 🦠💊. A former visiting scholar at UCLA (2018-2019), Dr. Xiao has published extensively in high-impact journals 📚. His work contributes to the rational use of antibiotics and combating multidrug resistance, advancing veterinary and human medicine alike. 🏆🔍

Publication Profile

Scopus

Education

Assoc. Prof. Dr. Xia Xiao is a leading veterinary microbiologist at Yangzhou University. He earned his Ph.D. in Veterinary Science from South China Agricultural University (2015) 🎓, specializing in bacteriophage-mediated antibiotic resistance. As a former visiting scholar at UCLA (2018-2019) 🌍, his research focuses on antimicrobial pharmacokinetics, novel antimicrobial agents, and bacterial resistance mechanisms 🦠💊. Since 2020, he has been an Associate Professor, contributing to advancements in antibiotic utilization and resistance control. His work plays a crucial role in improving both veterinary and human medicine. 📚

Experience

Assoc. Prof. Dr. Xia Xiao is a veterinary microbiologist at Yangzhou University, specializing in antimicrobial resistance 🦠💊. He earned his Ph.D. from South China Agricultural University (2015) 🎓, focusing on bacteriophage-mediated antibiotic resistance. As a Visiting Scholar at UCLA (2018-2019) 🌍, he expanded his research through international collaborations, enhancing his contributions to the global scientific community 🔬🤝. His work explores antibiotic pharmacokinetics, novel antimicrobial agents, and bacterial resistance strategies. Since 2020, he has been an Associate Professor, making impactful strides in veterinary and human medicine. 📚🏆

Focus Areas

Assoc. Prof. Dr. Xia Xiao is a veterinary microbiologist at Yangzhou University, specializing in antimicrobial resistance and antibiotic optimization 💊📊. He earned his Ph.D. from South China Agricultural University (2015) 🎓 and later expanded his research through international collaboration as a Visiting Scholar at UCLA (2018-2019) 🌍. His work focuses on pharmacokinetics-based antibiotic use, novel antimicrobial development, and strategies to combat bacterial resistance 🏥⚕️. His groundbreaking research on bacteriophage-mediated resistance transmission addresses global health challenges, making significant contributions to veterinary and medical microbiology. 📚🏆

Research Focus

Assoc. Prof. Dr. Xia Xiao’s research primarily focuses on antimicrobial resistance (AMR) 🦠💊, pharmacokinetics/pharmacodynamics (PK/PD) modeling 📊🧪, and bacterial resistance mechanisms 🔬🧫. Her work explores the role of resistance genes, such as mcr-1, blaNDM-5, and tet(X4), in multidrug-resistant pathogens, including Klebsiella pneumoniae and Escherichia coli. She investigates novel strategies to combat AMR, including using natural compounds 🌿, repurposed drugs 💡, and PK/PD-based optimization 📉📈. Her research has significant implications for developing effective treatments against drug-resistant infections in both humans and animals 🏥🐾.

Publication Top Notes

DNA Polymerase IV dinB Favors the Adaptive Fitness of mcr-carrying Bacteria Through a Negative Feedback Regulatory Mechanism

Acetylshikonin Derived From Arnebia euchroma (Royle) Johnst Kills Multidrug-Resistant Gram-Positive Pathogens In Vitro and In Vivo

Acetylshikonin reduces the spread of antibiotic resistance via plasmid conjugation

The Food Additive Benzaldehyde Confers a Broad Antibiotic Tolerance by Modulating Bacterial Metabolism and Inhibiting the Formation of Bacterial Flagella

Gramine sensitizes Klebsiella pneumoniae to tigecycline killing

Characterization of a cfr-bearing integrative and conjugative element in Proteus cibarius coharbouring tet(X6) on the chromosome